Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| I am very pleased with our progress during the third quarter, and I'm excited about what we are in the process of achieving |
| And therefore, we hope and we think that we may be able to show better mobilization and perhaps even reduce the number of mobilization cycles to a bare minimum and therefore, save a significant amount of time and discomfort for the sickle cell patients since that's the idea behind our value proposition there |
| And so we see that as a very key life cycle management upside for the company |
| We have a highly differentiated product profile based on our stronger and more consistent mobilization outcomes |
| We believe we are highly differentiated as a novel second-generation mobilization agent and that we have a significant value proposition for all stakeholders, that includes centers, patients and payers |
| We believe the differentiated clinical attributes APHEXDA will drive long-term adoption and allow it to evolve into the new standard of care for mobilization |
| Over time, we strongly believe that differentiation will outweigh drug price as centers adopt the best treatment paradigm for their patients |
| This encouraging feedback gives us great optimism the long-term opportunity that is in front of us |
| We are making consistent and steady progress |
| So listen, John, I mean, we’re happy, as Holly mentioned, we’re happy with the way things are progressing |
| As Phil indicated earlier, the addition of Motixafortide to G-CSF also allowed 88.3% of patients to undergo transplantation after only one apheresis session compared to 10.8% in the G-CSF, given the demonstrated performance of APHEXDA relative to the current treatment guidelines, we are confident that we will ultimately gain inclusion |
| With APHEXDA as a potential backbone of a new mobilization paradigm, we are optimistic that many more multiple myeloma patients will be candidates for this life extending procedure and will benefit from what we are calling an A-plus transplantation experience |
| These findings compare very favorably to historic partial response and disease control rate of 23% and 48%, respectively, reported with the current standard of care |
| Needless to say, we are excited about the potential of Motixafortide to form the backbone of new PDAC treatment regimens giving new hope to patients suffering from this very difficult to treat tumor type, while demonstrating the versatility of Motixafortide across both hematological and solid tumor cancers |
| So that's an area I think that we are spending perhaps a little bit more time than maybe we had originally the strong clinical data, which is our efficacy pillar the Phase 3 GENESIS data is resonating quite well |
| The combination also appeared to be well tolerated with a low incidence of neutropenia and infections in treated patients |
| Payers view the effects of clinical data very favorably |
| For the ability to more predictably and reliably achieve the target number of stem cells required for transplantation and fewer apheresis sessions can result in significant savings to payers over time |
| In closing, we are progressing through 2023 with significant momentum |
| In summary, I am very pleased with our launch progress to date |
| With the efficacy demonstrated in Phase 3 GENESIS trial, which supported the approval of effects to indecent indication, we believe we can overcome these challenges |
| We are launching our first therapy in stem cell mobilization and are making significant progress, raising awareness of the many benefits APHEXDA can bring to payers and transplant centers |
| As Phil indicated, the approval of APHEXDA for stem cell mobilization in multiple myeloma patients represents the first true advancement in stems mobilization in over a decade |
| In prior clinical trials, Gloria Biosciences has demonstrated an ability to enroll patients quickly, and we believe they will be able to complete this trial with similar efficiency |
| Both our commercial and medical affairs teams, which include many individuals with decades of experience in both stem cell mobilization and multiple myeloma are generating results in the early stages of this launch as we continue to engage with top transplant centers, physician leaders and payers on this exciting new treatment option |
| suggest that APHEXDA fills a significant unmet need for a more effective mobilization regimen, conferring benefits to centers, payers and patients alike |
| Increases shares can be in short supply at many transplant center and the potential for APHEXDA to allow for the collection of the targeted number of stem cells quite often in a single apheresis session should allow for the more efficient scheduling and utilization of those tiers |
| We have made substantial progress since our last quarterly update with our Stem Cell Mobilization program |
| So we believe they are uniquely positioned to explore the potential utility of Motixafortide in combination trials against this difficult to treat cancer |
| And so we feel quite comfortable from a cash perspective that we can meet everything that we need to do from a launch perspective in the near future |
| Statement |
|---|
| As we will cover in more detail shortly, the requirements for multiple apheresis session leads to potentially more adverse events, higher costs and tremendous inconvenience and mental hardship for patients |
| Since our last earnings call and as expected, multiple abbreviated new drug applications or ANDA have been approved for generic [indiscernible] leading to rapid and significant price erosion for the first-generation mobilization agent |
| In addition, the introduction of stronger induction therapies has further impaired mobilization, including drugs such as lenalidomide and natalizumab (ph), which are often given in combination |
| Also, as a reminder, multiple myeloma is the second most common hematologic malignancy and autologous stem cell transplantation remains the standard of care treatment and has been shown to prolong the lives of patients with this cancer type |
| Furthermore, in many cases, current mobilization treatments fail to reliably yield optimal number of stem cells to facilitate gene therapy |
| Unlike multiple myeloma patients, the current standard of care mobilization G-CSF carries significant risks and potential severe side effects for patients suffering from sickle cell disease |
| However, due to a number of factors, including an aging patient population and the increased use of three and four drug induction therapies, as Phil indicated, up to 47% of patients have had challenges collecting the target number of stem cells in one apheresis session |
| So I certainly understand the challenges -- we also know that both Vertex and Bluebird are looking at PDUFA dates in December here in the U.S., so that could be significant |
| And in addition, as Holly mentioned, these patients cannot receive G-CSF and therefore, it's that much more difficult to mobilize |
| Research and development expenses for the three months ended September 30, 2023 were $2.7 million, a decrease of $1.6 million or 37.6% compared to $4.3 million for the corresponding period last year |
| I apologize |
| And historically, depending on treatment regimens, up to 47% of patients have faced challenges mobilizing the target number of stem cell after one session |
| Net loss for the three months ended September 30, 2023, was $16 million compared to $6.8 million for the corresponding period last year |
| Net loss for the nine months ended September 30, 2023, amounted to $46.7 million compared to $19.2 million for the corresponding period last year |
| Further, notwithstanding the existence of lower-priced generic plerixafor |
| And first, I just wanted to extend my well wishes to everybody, not only for these difficult and turbulent times, but also for the holidays |
Please consider a small donation if you think this website provides you with relevant information